Signals
Ten Years of MS Data Make Delay Harder to Defend
A decade of OPERA follow-up shows durable relapse and disability control with ocrelizumab, while patients who started high-efficacy therapy later never fully caught up. The escalation debate now carries a long-term cost.
Menstrual Migraine Was Never Just Regular Migraine
Insurance is not access: Nearly half of insured adults with multiple conditions report delays or denials
University students moved less than adults in their 70s. Cardiometabolic prevention may be starting too late
The next medical AI dataset could come from donated bodies. Consent may be the harder problem
Heart calcium scans add little for most patients. Their real value may be in the uncertain middle
Obesity treatment is becoming a portfolio, not a product. Lilly’s EASD lineup shows what comes next
Medical AI can ace the benchmark and still fail the clinic. Real-world evidence is the next test
Alzheimer’s PET Is Becoming Data Infrastructure
Age does not affect maternal cardiovascular risk equally. California data show widening Black-White gaps
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.